NRX Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen, and welcome to the NRX Pharmaceuticals second quarter 2026 results conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. Should we require any operator assistance, you may press star zero. I would now like to turn the conference call over to Sebastian Gomez of Astor Partners. Please go ahead.

Thank you, operator, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities law. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the day hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued today and in the company's form 10-Q, which may be accessed from the investor page of the NRX Pharmaceuticals website. Joining me on today's call is Dr. Jonathan Javitt, our founder, chairman, and CEO, and Michael Abrams, our chief financial officer. Dr. Javitt will provide an overview of the company's progress during both the first half of the year and second quarter in particular, following which Michael Abrams will review our financial results. Following their prepared remarks, we will address investor questions. I will now turn the call over to Jonathan. Jonathan?

Thank you, Sebastian.